We examined the ligand-binding site of the 5-hydroxytryptamine 6 (5-HT 6 ) receptor using site-directed mutagenesis. Interactions with residues in two characteristic positions of transmembrane region V are important for ligand binding in several bioamine receptors. In the 5-HT 6 receptor, one of these residues is a threonine (Thr196), whereas in most other mammalian 5-HT receptors, the corresponding residue is alanine. After transient expression in human embryonic kidney 293 cells, we determined the effects of the mutation T196A on [ 3 H]d-lysergic acid diethylamide (LSD) binding and adenylyl cyclase stimulation. This mutation produced a receptor with a 10-fold reduced affinity for [ 3 H]LSD and a 6-fold reduced affinity for 5-HT. The potency of both LSD and 5-HT for stimulation of adenylyl cyclase was also reduced by 18-and 7-fold, respectively. The affinity of other N1-unsubstituted ergolines (e.g., ergotamine, lisuride) was reduced 10 -30-fold, whereas the affinity of N1-methylated ergolines (e.g., metergoline, methysergide, mesulergine) and other ligands, such as methiothepine, clozapine, ritanserin, amitriptyline, and mianserin, changed very little or increased. This indicates that in wild-type 5-HT 6 receptor, Thr196 interacts with the N1 of N1-unsubstituted ergolines and tryptamines, probably forming a hydrogen bond. Based on molecular modeling, a serine residue in transmembrane region IV of the 5-HT 2A receptor has previously been proposed to interact with the N1-position of 5-HT. When the corresponding residue of the 5-HT 6 receptor (Ala154) was converted to serine, no change in the affinity of twelve 5-HT 6 receptor ligands or in the potency of 5-HT and LSD could be detected, suggesting that this position does not contribute to the ligand binding site of the 5-HT 6 receptor.
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To date, 14 distinct mammalian 5-HT (serotonin) receptors have been identified. The known 5-HT receptors include a ligand-gated ion channel (5-HT 3 receptor) and 13 G proteincoupled receptors (1, 2) . Unlike the classic 5-HT receptors, the 5-HT 6 receptor was first discovered by cloning from rat striatal cDNA but had not been previously identified as a pharmacological entity in physiological or radioligand binding experiments (3, 4) . Subsequently, the human 5-HT 6 receptor was isolated by homology screening (5) . The highest levels of 5-HT 6 receptor mRNA are present in olfactory tubercle, nucleus accumbens, striatum, and hippocampus (3, 4, 6, 7) . In addition to these regions, 5-HT 6 receptor-like immunoreactivity was identified in frontal and entorhinal cortex and the molecular layer of the cerebellum (8) . The functional significance of this receptor has been investigated using intracerebroventricular injection of 5-HT 6 receptor-specific antisense oligonucleotides, which produced a behavioral syndrome, suggesting effects on dopaminergic and/or cholinergic neurotransmission (9, 10) .
The 5-HT 6 receptor displays a characteristic pharmacological profile, as was shown in competition studies with either 125 I-LSD or [ 3 H]5-HT, both of which bind to the 5-HT 6 receptor with high affinity (3) . Many nonselective compounds, such as tricyclic antidepressant drugs and a large number of antipsychotic agents, tryptamine, and ergoline derivatives, interact with the 5-HT 6 receptor (3, 11, 12) . Because no selective ligands are available, identification of functional 5-HT 6 receptors in physiological preparations can be only tentative. A model of the 5-HT 6 receptor binding site may suggest modifications of known ligands to improve the affinity and selectivity for this receptor. To verify and adapt models that have been proposed for other G protein-coupled receptors, we attempted to identify residues contributing to the ligand binding site of the 5-HT 6 receptor through the use of site-directed mutagenesis.
There is general agreement that for this class of bioamine receptors, the ligand binding site is formed by seven transmembrane helices present in all members of the family (13) (14) (15) . In these transmembrane regions, the 5-HT 6 receptor shows highest homology to other 5-HT receptors (36 -41% sequence identity), but the homology to adrenergic, dopamine, and histamine receptors is also quite high (30 -35% identity depending on which segments are included in the comparison). In site-directed mutagenesis and modeling studies with other bioamine receptors, several specific regions were consistently found to be involved in ligand binding and receptor activation. In transmembrane helix V of the hamster ␤ 2 -adrenergic receptor, replacement of either of two serine residues attenuated the activity of catecholamine agonists at the receptor (16) (Fig. 1) . Removal of the catechol hydroxyl moieties from the aromatic ring of the ligand mimicked the effects of the mutation, suggesting that in wild-type receptors, hydrogen bond interactions are formed between the serine residues and the meta-and para-hydroxyl group of agonists. These two or three characteristically spaced serine residues (one helix turn or three or four residues apart) were subsequently shown to contribute to agonist binding in ␣ 2A -and ␣ 1 -adrenergic receptors (17, 18) and both D 1 and D 2 dopamine receptors (19 -22) . In the histamine receptors, these positions are occupied by threonine and asparagine (H 1 receptor) or aspartate and threonine (H 2 ), and mutations of these residues also affect ligand binding (23) (24) (25) (26) . In all G protein-coupled 5-HT receptors cloned to date, the first of these "hydrogen bonding" positions is occupied by a serine or threonine residue and frequently preceded by another serine (see Fig. 1 ). In the 5-HT 1A receptor, a serine and a threonine residue are next to each other at this position. Replacement of either residue by alanine reduced the affinity of 5-HT and its ability to stimulate GTPase activity, suggesting the disruption of a normally present hydrogen bond with the hydroxyl-group on the indole ring of 5-HT (27) . The second potential hydrogen bonding position in transmembrane region V is occupied by an alanine in 11 of the 13 cloned mammalian G protein-coupled 5-HT receptor subtypes. The only exceptions are the rat and human 5-HT 6 receptors (threonine) and the human, pig, and squirrel monkey 5-HT 2A receptors (serine), whereas the rat 5-HT 2A receptor has an alanine residue in this position (like all other subtypes). This single amino acid variation is responsible for dramatic species differences in the affinity of N1-substituted or unsubstituted ergolines and tryptamines for rat compared with human, pig, or squirrel monkey 5-HT 2A receptors, as was demonstrated by reversal of the pharmacology by point mutations in both the human and rat receptor (28 -32) . This position contributes to the subtype selectivity of ligands because replacement of the wild-type alanine of the human 5-HT 2C receptor by serine changes the affinity of several ergoline compounds to values closer to their affinity for the human 5-HT 2A receptor, and vice versa (33) .
To determine whether this second potential hydrogen bonding position available in the 5-HT 6 receptor contributes to ligand binding, we replaced the threonine residue present at the corresponding position of the rat 5-HT 6 receptor (Thr196) with alanine (T196A), the residue present in most other mammalian 5-HT receptors.
Using a G protein-coupled receptor model based on the structure of bacteriorhodopsin, Hibert et al. (13) suggested a number of potential interactions of 5-HT with the 5-HT 2A receptor, including a hydrogen bond between the 5-hydroxyl group of 5-HT and a serine in transmembrane V (in the first hydrogen bonding position discussed above) and a second hydrogen bond between a serine residue in transmembrane IV and the indole-nitrogen (N1) of 5-HT (13) . This serine residue is conserved in most cloned mammalian 5-HT receptors with the exception of the 5-HT 1A receptors (glycine), 5-HT 4 receptor (proline), and 5-HT 6 receptors (alanine) (Fig.  2) . We tested whether the substitution of Ala154 by serine (A154S) (i.e., the introduction of a hydroxyl group) would allow the formation of a new hydrogen bond and thus change the affinity or agonist activity of 5-HT 6 receptor ligands.
Experimental Procedures
Cloning of the rat 5-HT 6 receptor and site-directed mutagenesis. A cDNA clone representing the 5-HT 6 receptor was generated from rat striatal mRNA by reverse transcription-polymerase chain reaction using primers based on the published rat 5-HT 6 Fig. 1 . Alignment of transmembrane region V of mammalian 5-HT and related bioamine receptors. Bold, conserved serine and threonine residues in the first potential hydrogen bonding position(s) of the 5-HT receptors. The role of the outlined residues in ligand binding has been examined in the receptors listed and/or in species homologues with the help of site-directed mutagenesis. In the current study, Thr196 of the 5-HT 6 receptor has been mutated to alanine, the residue found in most other 5-HT receptors. sequence (3) 1 and subcloned into the plasmid pAMP1 using the CloneAmp system (Life Technologies, Eggenstein, Germany). One clone was identified that matched exactly the sequence of Kohen et al. (5) 2 with the exception of a single base exchange that did not alter 1 GenBank accession number L03202. 2 GenBank accession number L41146. (12) . An EcoRI/XbaI restriction fragment of the pAMP1-5-HT 6 construct was ligated into the expression vector pcDNA1.1amp (InVitrogen, San Diego, CA) and into the phagemid pAlter (Promega, Madison, WI). Mutagenesis was performed using the Altered Sites Mutagenesis kit (Promega). Thr196 was mutated to alanine (T196A) using the oligonucleotide 5Ј-GTCCGGCGTCGCCTTTTTCCT-3Ј. Ala154 was mutated to serine (A154S) using the mutagenic oligonucleotide 5Ј-GGTGCCTGGAGCCTCAGCGCGCTTGCCTCCTTC-3Ј. This oligonucleotide introduced an additional silent mutation, creating a new BssH II restriction site. After transfer into the expression vector pcDNA1.1amp, mutations were confirmed by sequencing the entire coding region using an automated fluorescent sequencing system (ALF; Pharmacia, Vienna, Austria).
Transient transfection of HEK 293 cells. HEK 293 cells were maintained in DMEM plus 10% FBS containing 100 IU/ml penicillin and 100 g/ml streptomycin in a humidified atmosphere (5% CO 2 ). HEK 293 cells (80-90% confluent in 75-or 185-cm 2 flasks) were cotransfected with the construct pcDNA1.1amp-5-HT 6 (8 or 20 g) containing the coding region of wild-type or mutant 5-HT 6 receptor according to the Lipofectamine transfection protocol (Life Technologies). After 1 day, the medium was replaced by fresh DMEM plus 10% FBS.
Membrane preparation and receptor binding assays. Two days after transfection with the pcDNA1.1amp constructs containing mutant or wild-type 5-HT 6 receptor coding regions, the cells were detached with ice-cold 50 mM Tris⅐HCl, pH 7.4, containing 10 mM MgCl 2 and 0.5 mM EDTA. The cells were disrupted using a Polytron homogenizer (15 sec at maximal speed) at a concentration corresponding to ϳ2 ϫ 10 6 cells/ml. This homogenate was centrifuged at 50,000 ϫ g for 30 min, resuspended in the same volume, and centrifuged again. At this stage, the resulting pellets were either stored at Ϫ20°or used immediately in binding assays. 5-HT 6 receptor binding assays were performed using [ Incubations were performed at 37°for 60 min and terminated by rapid filtration through Whatman (Maidstone, UK) GF/B filters pretreated with polyethyleneimine (0.3%). The filters were washed three times with 2 ml of Tris⅐HCl (50 mM; pH 7.4), and the radioactivity retained on the filters was measured by scintillation spectroscopy in 2 ml of scintillation fluid. All experiments were performed in triplicate and repeated at least three times. Values are given as mean Ϯ standard error. Data were analyzed using the programs EBDA and LIGAND (34, 35) . Protein concentrations were determined using the BCA method (Pierce Chemical, Indianapolis, IN).
Adenylyl cyclase measurements. Two days after transfection, cells grown in DMEM plus 10% FBS (dialyzed) were washed once with DMEM without phenol red (DMEM Ϫ ), detached with PBS plus 1 mM EDTA, and washed twice with DMEM Ϫ (470 ϫ g, 5 min). The final cell density was adjusted to ϳ1.25 ϫ 10 6 cells/ml. Aliquots of 80 l were transferred to 96-well plates (ca. 10 5 cells/well) and incubated at 37°in a humidified atmosphere for 30 min. 5-HT or LSD, combined with pargyline and the phosphodiesterase inhibitor Ro 20-1724, was added in a volume of 20 l/well (final incubation volume, 100 l/well; final concentration of agonists, 10 Ϫ10 to 10
pargyline, 20 M; Ro 20-1724, 100 M). After 20 min at 37°in a humidified atmosphere (5% CO 2 ), the incubation was terminated by the addition of 200 l of ethanol/well. After Ն2 hr at Ϫ20°, the plates were centrifuged for 5 min at 470 ϫ g (4°), and 75-l aliquots of the supernatant were transferred to OptiPlates (Packard, Meriden, CT), evaporated under vacuum, and resuspended in 0.05 M acetate buffer. The concentration of cAMP was determined using the BIOTRAK cAMP [ 125 I] Scintillation Proximity Assay system (Amersham) adapted to 96-well plates. The concentration effect curves were analyzed using the equation E ϭ B ϩ E max * x/(EC 50 ϩ x), where E and E max are the measured and maximum effects (cAMP/well), respectively; B is the basal cAMP level, and x is the concentration of agonist.
Materials.
[ 3 H]LSD (specific activity, 82 Ci/mmol) was obtained from Amersham. 5-HT was from FLUKA (Buchs, Switzerland), and ergotamine was from Sigma (Buchs, Switzerland). Mesulergine, metergoline, methysergide, lisuride, methiothepine, clozapine, amitriptyline, ritanserin, mianserin, and pargyline were purchased from Research Biochemicals (Natick, MA). DMEM, FBS, penicillin, streptomycin, and geneticin were obtained from Gibco Life Technologies (Fig. 3) . The K d values for wild-type 5-HT 6 receptor and mutant A154S were not significantly different (1.9 Ϯ 0.3 and 2.1 Ϯ 0.1 nM, respectively). However, the affinity of [ Comparison of the pharmacological profile of wild-type and mutant receptors. In competition assays with [ 3 H] LSD, the affinity of the endogenous agonist 5-HT for the mutant receptor T196A was reduced 6-fold compared with wild-type 5-HT 6 receptor (Fig. 4, Table 1 ). The affinities of the N1-unsubstituted ergolines ergotamine and lisuride were reduced 16-and 34-fold, respectively (Fig. 4, Table 1 ). In contrast, the affinity of N1-methylated ergolines for the mutant T196A did not change (metergoline) or increased 4-7-fold (methysergide, mesulergine) ( Table 1 ) (see Fig. 5 for structures). The affinity of several other high affinity 5-HT 6 receptor ligands that are neither tryptamine nor ergoline derivatives (methiothepine, clozapine, amitriptyline, ritanserin, and mianserin) did not change significantly (Table 1 ). The Hill slopes of the ligands tested were not significantly different between wild-type and T196A mutant 5-HT 6 receptors, with the exception of lisuride and ritanserin, which had lower Hill slopes at the mutant receptor ( p Ͻ 0.05, unpaired t test). Neither of the compounds examined showed significant changes in affinity for the second mutant (A154S) (Fig. 4 ; Table  1 ).
Comparison of the functional properties of wild-type and mutant 5-HT 6 (Fig. 6) .
Change in free energy. For LSD and 5-HT, the change in binding energy ⌬(⌬G) introduced by the mutation T196A could be calculated both from the EC 50 values determined in adenylyl cyclase stimulation assays and the K d and K i values determined in [ 3 H]LSD binding experiments ( Table 2) . The values calculated for 5-HT (5.1 and 4.6 kJ/mol) were lower than those observed for LSD (7.5 and 7.3 kJ/mol). The change in free energy observed for ergotamine (7.2 kJ/mol) and lisuride (9.1 kJ/mol) calculated from the K i values was also higher than for 5-HT.
Discussion
The 5-HT 6 receptor has a characteristic pharmacological profile that distinguishes it from other 5-HT receptors, but so far, no selective 5-HT 6 receptor ligands have been described. We attempted to identify specific interactions between the 5-HT 6 receptor and nonselective ligands to allow the adaptation of existing G protein-coupled receptor models to the binding site of the 5-HT 6 receptor. Eventually, such models could be used to suggest structural modifications that might improve ligand affinity and selectivity. Several groups have proposed three-dimensional models of the ligand binding site of other G protein-coupled 5-HT receptors (13, 36 -38) . As a first step, we looked for characteristic differences in the amino acid sequence of the 5-HT 6 receptor compared with other 5-HT receptors in positions that had been suggested to form part of the ligand binding site.
One of the interactions of 5-HT with the 5-HT 2A receptor suggested by Hibert et al. (13) was a hydrogen bond between a serine residue in transmembrane region IV and the indolenitrogen (N1) of 5-HT. This serine residue is conserved in the majority of cloned mammalian 5-HT receptors, with the exception of the 5-HT 1A receptors (glycine), 5-HT 4 receptor (proline), and 5-HT 6 receptors (alanine). We tested whether substitution of Ala154 by serine (i.e., the introduction of a new hydroxyl group at this position) would allow the formation of a new hydrogen bond, thus changing the affinity or agonist activity of 5-HT 6 receptor has not yet been experimentally verified to our knowledge.
In contrast, removal of a potential hydrogen bond forming site in transmembrane helix five of the 5-HT 6 receptor by changing Thr196 to alanine (the residue present in most other mammalian 5-HT receptors) selectively reduced the affinity of the natural agonist 5-HT (a N1-unsubstituted indoleamine) and that of several N1-unsubstituted ergolines (LSD, lisuride, ergotamine) while not affecting the affinity of the N1-methylated compound metergoline and increasing the affinity of the N1-methylated ergolines mesulergine and methysergide. The potency of 5-HT and LSD in cAMP accumulation experiments was reduced by the same factor as the affinity determined in binding experiments. The change in free energy [⌬(⌬G)] for the interaction with 5-HT calculated from the ratio of either the EC 50 values (5.1 kJ/mol) or K i values (4.6 kJ/mol) was less than that for LSD (7.5 and 7.3 kJ/mol, respectively). The other N1-unsubstituted ergolines tested in [ 3 H] LSD binding assays, ergotamine (7.2 kJ/mol) and lisuride (9.1 kJ/mol), also showed larger changes in their free energy than 5-HT. However, all values were in the range expected for hydrogen bonds (2.1-7.5 kJ/mol ϭ 0.5-1.8 kcal/ mol) (39) . This is consistent with the existence of a hydrogen bond between the indole N of 5-HT and N1-unsubstituted ergoline compounds and the hydroxyl group of Thr196 in the wild-type 5-HT 6 receptor (Fig. 7) . The efficacy of adenylyl cyclase coupling was not affected by exchanging Thr196 for alanine because the maximum levels of adenylyl cyclase stimulation obtained for this mutant and wild-type receptor were similar and the partial agonist character of LSD was unchanged. The decreased potency of both 5-HT and LSD observed in the cAMP accumulation experiments with mutant T196A presumably is a direct consequence of the reduction in binding affinity that is detected in the [ 3 H] LSD binding assays. The expression levels reached for wild-type and mutant receptors were similar, so effects due to changes in the ratio of receptor to G proteins can be excluded. The affinities of metergoline and those of several antagonists with nonergoline structures were not significantly decreased. This shows that the overall structure of the receptor has been well preserved and the observed reduction of the affinity of 5-HT and N-1 unsubstituted ergolines must be due to the elimination of a specific interaction of the side chain of Thr196 and these ligands. The increased affinity of mesulergine and methysergide could be the result of the elimination of an unfavorable steric interaction between the methyl group in the N1 position of these ligands and the hydroxyl and methyl group of Thr196 in the wild-type receptor that are removed in the T196A mutant (Fig. 7) . Metergoline may bind to the receptor in a slightly different orientation that is not influenced by the size of the side chain of residue 196.
The hydrogen bond that can be formed between the N1 of ergoline compounds and the hydroxyl group of Thr196 is analogous to the interaction of these compounds with the amino acid present in the corresponding position in human, pig, and squirrel monkey 5-HT 2A receptor (Ser242) (28 -32) . All other cloned mammalian 5-HT receptors, including the rat 5-HT 2A receptor, contain an alanine residue at this position (Fig. 1) . N1-Unsubstituted ergolines and tryptamines have a higher affinity for human, pig, and squirrel monkey 5-HT 2A receptors because they can form a hydrogen bond with the serine residue present in these species. N1-Substituted ergolines have a higher affinity for the rat 5-HT 2A receptor and lower affinity for human, pig, and squirrel monkey 5-HT 2A receptors, presumably because of unfavorable steric interactions with the hydroxyl group present in the serine-containing species subtypes. Replacement of the serine residue present in the human 5-HT 2A receptor by alanine results in a pharmacology similar to that of the rat receptor, and replacement of the alanine in the rat sequence by serine did the reverse (28, 29) . This position also contributes to the selectivity of ligands between the human 5-HT 2A receptor and the human 5-HT 2C receptor (33) .
Among 5-HT receptors, the interaction between agonists [3H]-LSD binding assays and the second hydrogen bonding site in transmembrane region V is unique to the 5-HT 6 receptor and the species subtypes of the 5-HT 2A receptor mentioned above. In contrast, all 5-HT receptors cloned to date contain either a serine or a threonine residue one helix turn (three residues) closer to the extracellular surface (Ser193 in the 5-HT 6 receptor).
Mutation of the corresponding residue in the 5-HT 1A receptor (a threonine) to alanine decreased the affinity and agonist activity of 5-HT (27) . This hydrogen bond with the 5-hydroxyl-group of the indole ring of 5-HT may thus be present in the binding site of all 5-HT receptors. In the related cationic amine receptors (i.e., ␣ 1A -, ␣ 2A -, and ␤ 2 -adrenergic receptors; D 1 and D 2 dopamine receptors; and H 1 and H 2 histamine receptors), both positions are occupied by potential hydrogen bond-forming residues, and in most cases, both positions seem to contribute to the ligand binding site. Of particular interest with respect to our results is the suggestion that the asparagine residue present at the position corresponding to Thr196 in the histamine H 1 receptor may interact with the -nitrogen of the imidazole ring of histamine (24) . This -nitrogen can assume the same relative position to the positively charged -nitrogen of histamine as the indole (N1) nitrogen of 5-HT to the -nitrogen of 5-HT. The histamine H 2 receptor contains a threonine residue at this position, and mutation of this residue also affects ligand binding and agonist potency (23) .
The combination of site-directed mutagenesis (guided by knowledge obtained for related receptors) with a series of related ligands differing in a particular structural feature has allowed the identification of a specific interaction between Thr196 in transmembrane region V of the 5-HT 6 receptor and the indole nitrogen of N1-unsubstituted ergolines and tryptamines. These results provide information that can be used to improve models of 5-HT 6 receptor/ligand interactions and may contribute to the design of selective drugs for this receptor type.
